IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer

Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be define...

Descripción completa

Detalles Bibliográficos
Autores: Colomer, Carlota, Margalef, Pol, Villanueva Garatachea, Alberto, Vert, Anna, Pecharroman, Irene, Sole, Laura, González Farré, Mónica, Alonso, Josune, Montagut Viladot, Clara, Martínez Iniesta, María, Bertran, Joan, Borràs, Eva, Iglesias, Mar, Sabidó Aguadé, Eduard, Bigas Salvans, Anna, Boulton, Simon J., Espinosa, Lluís
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/171364
Acceso en línea:https://hdl.handle.net/2445/171364
Access Level:acceso abierto
Palabra clave:Càncer
Reparació de l'ADN
Cancer
DNA repair
Descripción
Sumario:Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment.